Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Completed
National Cancer Institute (NCI)
Phase 1
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Motexafin
gadolinium may increase the effectiveness of radiation therapy by making tumor cells more
sensitive to radiation.
PURPOSE: Phase I trial to study the effectiveness of motexafin gadolinium plus radiation
therapy in treating patients who have newly diagnosed glioblastoma multiforme.
Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Completed
Jonsson Comprehensive Cancer Center
Phase 1
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Motexafin
gadolinium may increase the effectiveness of radiation therapy by making tumor cells more
sensitive to radiation.
PURPOSE: Phase I trial to study the effectiveness of motexafin gadolinium plus radiation
therapy in treating patients who have newly diagnosed glioblastoma multiforme.
Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas
Completed
National Cancer Institute (NCI)
Phase 1
RATIONALE: New imaging procedures such as the use of gadolinium texaphyrin with MRI may
improve the ability to detect the extent of gliomas.
PURPOSE: Phase I trial to study the effectiveness of gadolinium texaphyrin used with
MRI-guided surgery in treating patients with high-grade glioma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
